ABSTRACT
Introduction In addition to the original monovalent vaccines available for SARS-CoV-2, bivalent vaccines covering wild-type (WT) and Omicron BA.1 are also available. However, there is a lack of real-world data on the effectiveness of bivalent vaccines as second boosters on the dominant Omicron sublineages, including BA.2 and BA.5.
Methods This prospective longitudinal cohort study was conducted at Toyama University Hospital, a tertiary medical center in Japan. Participants (n = 565) who received the first booster vaccination were followed up until 2 weeks after the second booster dose of the monovalent mRNA-1273 (WT group, n = 168) and bivalent BNT162b2 (WT+BA.1 group, n = 23) vaccines. Participants with previous SARS-CoV-2 infections were excluded from the study. Anti-receptor-binding domain (RBD) antibody levels and neutralizing activity were measured. Vaccine-related symptoms were also assessed using a questionnaire after the second booster dose.
Results The anti-RBD antibody levels after the second booster dose in the WT and WT+BA.1 group were similar (median [inter quartile], 26262.0 [16951.0–38137.0] U/mL vs. 24840.0 [14828.0–41460.0] U/mL, respectively). Although the neutralization activity of the pooled sera of the WT+BA.1 group was the lowest against BA.5, the activities against BA.2 and BA.5 were higher than those of the WT group in both pseudotyped and live virus assays. Vaccine-related symptoms, including systemic and local symptoms, were strongly correlated with anti-RBD antibody levels and neutralizing titers with significant differences.
Conclusion The second booster dose of the bivalent (WT/Omicron BA.1) vaccine induced higher neutralizing activity against BA.2 and BA.5 than that of the original monovalent vaccine.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Research Program on Emerging and Re-emerging Infectious Diseases from the AMED (grant number JP20he0622035) (YM, HT, and YY) and (grant number JP21fk0108588) (YM and HT), a research funding grant from the president of the University of Toyama (YM, NH, and YY), Toyama Pharmaceutical Valley Development Consortium (YM, NH, and YY), Morinomiyako Medical Research Foundation (HK), Kurozumi Medical Foundation (HK), The Hokuriku Bank grant-in-aid for Young Scientists (HK), and Japan Society for the Promotion of Science (JSPS) KAKENHI grant number JP22K20768 (HK). The funding bodies played no role in the design of the study, collection, analysis, or interpretation of data, nor in writing the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was performed in accordance with the Declaration of Helsinki and approved by the ethical review board of the University of Toyama (approval No.: R2019167).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Authorship statement Conceptualization: HK, YMo; Methodology: HK, YMo, and HT; Validation: HK and YMo; Formal Analysis: HK and YMo; Investigation: HK, YMo, HY, YYo, MK, YuMu, KK (neutralizing assay), and HN (commercial antibody test); Resources: HT, YS (generating pseudotyped viruses), CO, YMa (generating plasmids), HK, YT, MK, YMu, KK, AU, YMi, and KN (serum sample collection); Data Curation: HK and YMo; Writing–Original Draft Preparation: HK, YMo and HT; Writing–Review and Editing: HK, YMo, and HT; Visualization: HK, YMo; Supervision: YMa, HN, and YYa; Project Administration: YMo and YYa; Funding acquisition: HK, YMo, HT, HN, and YYa
All authors meet the ICMJE authorship criteria.1
1 SARS-CoV-2: severe acute respiratory syndrome coronavirus 2, COVID-19: coronavirus disease 2019, VOC: Variant of Concern, htCRNT: high throughput chemiluminescence reduction neutralization test, RBD: receptor-binding domain, 2wA3D: 2 weeks after the third dose, 3mA3D: 3 months after the third dose, 6mA3D: 6 months after the third dose, 2wA4D: 2 weeks after the fourth dose, DMEM: Dulbecco’s modified Eagle’s medium, NT50: half-maximal neutralizing titer, IQR: interquartile range, VSVs: vesicular stomatitis viruses
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos